Advertisement

World Journal of Surgery

, Volume 28, Issue 9, pp 870–875 | Cite as

Treatment and Risk Factors for Recurrence after Curative Resection of Gastrointestinal Stromal Tumors of the Stomach

  • Yoshinari Mochizuki
  • Yasuhiro KoderaEmail author
  • Seiji Ito
  • Yoshitaka Yamamura
  • Yukihide Kanemitsu
  • Yasuhiro Shimizu
  • Takashi Hirai
  • Kenzo Yasui
  • Ken-ichi Inada
  • Tomoyuki Kato
Original Scientific Reports

Abstract

The current definitive treatment for gastrointestinal stromal tumor (GIST) of the stomach is complete resection. GIST has a highly variable clinical course, and recurrent disease sometimes develops despite curative treatment. Although several known risk factors for recurrence exist, adequate treatment strategies are lacking. This study evaluated factors associated with relapse after curative treatment. Sixty patients with gastric GIST were identified from a hospital disease registry database. Clinicopathologic characteristics of these patients were reviewed and the Cox proportional hazards regression analysis was used to identify recurrent risk factors. With a median follow-up of 60 months (range 5–286 months), recurrence occurred in eight (13%) patients, three of whom underwent resection of the recurrent disease and are alive to date. Univariate analysis demonstrated that invasion of the adjacent organs (p = 0.0005), tumor size (p = 0.0046), and expression of proliferative markers [MIB-1 proliferative index (PI) ≥ 10%] (p = 0.0001) were significant risk factors for recurrence. Multivariate analysis with these three factors as variables revealed that only MIB-1 PI was a significant independent risk factor for recurrence (p = 0.0051). In conclusion, surgical resection may be indicated whenever a recurrent GIST is considered resectable. A high MIB-1 PI was identified as an independent indicator of risk for recurrent disease following curative surgery.

Keywords

Complete Resection Gastrointestinal Stromal Tumor Wedge Resection Proximal Gastrectomy Gastric Gist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    McGrath, PC, Neifeld, JP, Lawrence, W,Jr,  et al. 1987Gastrointestinal sarcomas. Analysis of prognostic factorsAnn. Surg.206706710PubMedGoogle Scholar
  2. 2.
    Ng, EH, Pollock, RE, Munsell, MF,  et al. 1992Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and stagingAnn. Surg.2156877PubMedGoogle Scholar
  3. 3.
    Suster, S 1996Gastrointestinal stromal tumorsSemin. Diagn. Pathol.13297313PubMedGoogle Scholar
  4. 4.
    Kindblom, LG, Remotti, HE, Aldenborg, F,  et al. 1998Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of CajalAm. J. Pathol.15212591269PubMedGoogle Scholar
  5. 5.
    Evans, HL 1985Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 yearsCancer5622422250PubMedGoogle Scholar
  6. 6.
    Fujimoto, Y, Nakanishi, Y, Yoshimura, K,  et al. 2003Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patientsGastric Cancer63948CrossRefPubMedGoogle Scholar
  7. 7.
    Miettinen, M, El-Rifai, W, Sobin, L,  et al. 2002Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a reviewHum. Pathol.33478483CrossRefPubMedGoogle Scholar
  8. 8.
    Pidhorecky, I, Cheney, RT, Kraybill, WG,  et al. 2000Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and managementAnn. Surg. Oncol.7705712PubMedGoogle Scholar
  9. 9.
    Koga, H, Ochiai, A, Nakanishi, Y,  et al. 1995Reevaluation of factors in gastric leiomyosarcomaAm. J. Gastroenterol.9013071312PubMedGoogle Scholar
  10. 10.
    Pierie, JP, Choudry, U, Muzikansky, A,  et al. 2001The effect of surgery and grade on outcome of gastrointestinal stromal tumorsArch. Surg.136383389CrossRefPubMedGoogle Scholar
  11. 11.
    DeMatteo, RP, Lewis, JJ, Leung, D,  et al. 2000Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survivalAnn. Surg.2315158CrossRefPubMedGoogle Scholar
  12. 12.
    Kwon, SJ 2001Surgery and prognostic factors for gastric stromal tumorWorld J. Surg.25290295CrossRefPubMedGoogle Scholar
  13. 13.
    Skandalakis JE, Gray SW, Shepard D, et al. Smooth muscle tumors of the alimentary tract. Springfield, IL, Charles C Thomas, 1960;79–80Google Scholar
  14. 14.
    Remine, WH 1970Gastric sarcomasAm. J. Surg.120320323PubMedGoogle Scholar
  15. 15.
    Bandoh, T, Isoyama, T, Toyoshima, H 1993Submucosal tumors of the stomach: a study of 100 operative casesSurgery113498506PubMedGoogle Scholar
  16. 16.
    Carson, W, Karakousis, C, Douglass, H,  et al. 1994Results of aggressive treatment of gastric sarcomaAnn. Surg. Oncol.1244251PubMedGoogle Scholar
  17. 17.
    Shiu, MH, Farr, GH, Papachristou, DN,  et al. 1982Myosarcomas of the stomach: natural history, prognostic factors and managementCancer49177187PubMedGoogle Scholar
  18. 18.
    Lindsay, PC, Ordonez, N, Raaf, JH 1981Gastric leiomyosarcoma: clinical and pathological review of fifty patientsJ. Surg. Oncol.18399421PubMedGoogle Scholar
  19. 19.
    Chen, H, Pruitt, A, Nicol, TL,  et al. 1998Complete hepatic resection of metastases from leiomyosarcoma prolongs survivalJ. Gastrointest. Surg.2151155CrossRefPubMedGoogle Scholar
  20. 20.
    DeMatteo, RP, Shah, A, Fong, Y,  et al. 2001Results of hepatic resection for sarcoma metastatic to liverAnn. Surg.234540547CrossRefPubMedGoogle Scholar
  21. 21.
    Kodera, Y, Ito, S, Yamamura, Y,  et al. 2003Clinical relevance of follow-up after curative surgery for gastric carcinomaAnn. Surg. Oncol.10898902CrossRefPubMedGoogle Scholar
  22. 22.
    Roy, M, Sommers, SC 1989Metastatic potential of gastric leiomyosarcomaPathol. Res. Pract.185874877PubMedGoogle Scholar
  23. 23.
    Baak, JPA 1990Mitosis counting in tumorsHum. Pathol.21683685CrossRefPubMedGoogle Scholar
  24. 24.
    Demarchi, LM, Reis, MM, Palomino, SA,  et al. 2000Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lungMod. Pathol.13511520CrossRefPubMedGoogle Scholar
  25. 25.
    Kikuyama, S, Kubota, T, Shimizu, K,  et al. 1998Ki-67 antigen expression in relation to clinicopathological variables and prognosis in gastric cancerOncol. Rep.5867870PubMedGoogle Scholar
  26. 26.
    Trihia, H, Murray, S, Price, K,  et al. 2003Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors—a surrogate marker?Cancer9713211331CrossRefPubMedGoogle Scholar
  27. 27.
    Ma, CK, Peralta, MN, Amin, MB,  et al. 1997Small intestinal stromal tumors: a clinicopathologic study of 20 cases with immunohistochemical assessment of cell differentiation and the prognostic role of proliferation antigensAm. J. Clin. Pathol.108641651PubMedGoogle Scholar
  28. 28.
    Goldblum, JR, Appelman, HD 1995Stromal tumors of the duodenum. A histologic and immunohistochemical study of 20 casesAm. J. Surg. Pathol.197180PubMedGoogle Scholar
  29. 29.
    Toquet, C, Neel, JC, Guillou, L,  et al. 2002Elevated (> or = 10%) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumor patients: a study of 35 casesDig. Dis. Sci.4722472253CrossRefPubMedGoogle Scholar
  30. 30.
    Hasegawa, T, Matsuno, Y, Shimoda, T,  et al. 2002Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 gradeHum. Pathol.33669676CrossRefPubMedGoogle Scholar
  31. 31.
    Joensuu, H, Roberts, PJ, Sarlomo-Rikala, M,  et al. 2001Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumorN. Engl. J. Med.34410521056CrossRefPubMedGoogle Scholar
  32. 32.
    Wu, PC, Langerman, A, Ryan, CW,  et al. 2003Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) eraSurgery13656665CrossRefGoogle Scholar
  33. 33.
    Demetri, GD, Mehren, M, Blanke, CD,  et al. 2002Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsN. Engl. J. Med.347472480CrossRefPubMedGoogle Scholar
  34. 34.
    Nakanishi, H, Mochizuki, Y, Kodera, Y,  et al. 2003Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP) – tagged human gastric cancer cell lineCancer Sci.94112118PubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2004

Authors and Affiliations

  • Yoshinari Mochizuki
    • 1
  • Yasuhiro Kodera
    • 2
    Email author
  • Seiji Ito
    • 1
  • Yoshitaka Yamamura
    • 1
  • Yukihide Kanemitsu
    • 1
  • Yasuhiro Shimizu
    • 1
  • Takashi Hirai
    • 1
  • Kenzo Yasui
    • 1
  • Ken-ichi Inada
    • 3
  • Tomoyuki Kato
    • 1
  1. 1.Department of Gastroenterological SurgeryAichi Cancer Center HospitalNagoyaJapan
  2. 2.Department of Surgery IINagoya University School of MedicineNagoyaJapan
  3. 3.Division of Oncological PathologyAichi Cancer Center Research InstituteNagoyaJapan

Personalised recommendations